Sponsor Check › Person
Related person on Form D filings · address states as listed: CA, MA, WA, TX · listed Apr 7, 2009 → Jun 17, 2026
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:16 AM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:16 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:16 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
0 of 48 offerings report sales commissions; 2 report finder's fees totalling $2,150,345; 9 report proceeds to related persons totalling $9,469,028. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jun 17, 2026 D File 021-587687 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. | None listed on this filing |
| EDGAR ↗ | Nov 17, 2025 D File 021-564231 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. | None listed on this filing |
| EDGAR ↗ | May 6, 2025 D File 021-545368 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 11, 2024 D/A File 021-480968 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 2, 2024 D File 021-525614 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 2, 2024 D File 021-520416 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 22, 2024 D File 021-511175 | $0 | $0 | $0 No amounts other than ordinary course employment compensation is being paid to officers and directors. | None listed on this filing |
| EDGAR ↗ | Aug 18, 2023 D File 021-490085 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 12, 2023 D File 021-481584 | $0 | $0 | $4,800,000 (est.) The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period. | None listed on this filing |
| EDGAR ↗ | Nov 15, 2021 D File 021-420973 | $0 | $0 | $250,000 (est.) Ordinary salary for two executive officers; no cash compensation for any members of the Board. | None listed on this filing |
| EDGAR ↗ | Nov 3, 2021 D File 021-419677 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 9, 2021 D/A File 021-287679 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 31, 2021 D File 021-394093 | $0 | $0 | $1,400,000 (est.) The amount reflects payment of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period. | None listed on this filing |
| EDGAR ↗ | Mar 17, 2021 D File 021-392587 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 13, 2020 D/A File 021-310231 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 28, 2019 D File 021-347553 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 6, 2018 D File 021-320707 | $0 | $0 | $1,200,000 (est.) The amount reflects payments of accrued and unpaid bonuses from periods prior to the offering and anticipated salary to the listed executive officers and potential bonus payments for the following 24-month period. | None listed on this filing |
| EDGAR ↗ | Jul 19, 2018 D File 021-317252 | $0 | $0 | $0 | N/A no CRD number reported |
| EDGAR ↗ | Mar 23, 2017 D/A File 021-249440 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 10, 2016 D File 021-274296 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 9, 2016 D File 021-270385 | $0 (est.) | $0 (est.) | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 11, 2015 D File 021-241545 | $0 | $0 | $18,288 | None listed on this filing |
| EDGAR ↗ | May 8, 2015 D File 021-239429 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 7, 2015 D File 021-239360 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 5, 2015 D/A File 021-214739 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2014 D File 021-225481 | $0 | $1,950,345 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Aug 25, 2014 D File 021-223549 | $0 | $0 | $0 (est.) | None listed on this filing |
| EDGAR ↗ | Jun 13, 2014 D File 021-219207 | $0 | $0 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Nov 18, 2013 D/A File 021-166855 | $0 | $0 | $740 | None listed on this filing |
| EDGAR ↗ | Sep 4, 2013 D/A File 021-200459 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 2, 2013 D File 021-200634 | $0 | $0 | $600,000 (est.) | None listed on this filing |
| EDGAR ↗ | Jul 29, 2013 D/A File 021-200360 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 13, 2013 D File 021-197911 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 16, 2013 D File 021-195083 | $0 | $0 | $600,000 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 26, 2013 D File 021-193896 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 28, 2012 D File 021-189143 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 12, 2012 D File 021-184023 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 6, 2012 D File 021-183709 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 23, 2012 D/A File 021-163369 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 23, 2011 D/A File 021-165656 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 14, 2011 D File 021-162881 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 14, 2011 D File 021-158369 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 4, 2011 D File 021-156203 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 18, 2010 D File 021-142195 | $0 | $0 | $600,000 (est.) | None listed on this filing |
| EDGAR ↗ | Mar 17, 2010 D File 021-71676 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 22, 2010 D File 021-76805 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 20, 2009 D/A File 021-96106 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 7, 2009 D File 021-105860 | $0 | $200,000 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Qlaris Bio, Inc. | Director | Jun 17, 2026 | D | $3,946,659 similar: $2,000,000–$19,999,994 | $3,946,659 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Qlaris Bio, Inc. | Director | Nov 17, 2025 | D | $5,641,600 similar: $2,000,000–$19,999,994 | $5,641,600 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OncoResponse, Inc | Director | May 6, 2025 | D | Indefinite similar: $2,000,000–$19,999,994 | $5,999,138 | 9 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Antiva Biosciences, Inc. | Director | Oct 11, 2024 | D/A | $52,999,990 similar: $2,000,000–$19,999,994 | $38,535,985 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Hyalex Orthopaedics, Inc. | Director | Oct 2, 2024 | D | $18,124,761 similar: $829,831–$9,999,998 | $14,874,761 | 7 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Glooko, Inc. | Director | Aug 2, 2024 | D | $124,000,000 similar: $829,831–$9,999,998 | $0 | 0 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Qlaris Bio, Inc. | Director | Apr 22, 2024 | D | $24,032,554 similar: $2,000,000–$19,999,994 | $24,032,554 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Glooko, Inc. | Director | Aug 18, 2023 | D | $67,000,000 similar: $829,831–$9,999,998 | $0 | 0 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OncoResponse, Inc | Director | May 12, 2023 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $13,915,153 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Antiva Biosciences, Inc. | Director | May 5, 2023 | D | $52,999,990 similar: $2,000,000–$19,999,994 | $26,565,771 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Alchera Inc | Director | Nov 15, 2021 | D | Indefinite similar: $1,500,000–$10,000,000 | $5,202,580 | 56 similar: 1–11 | $2,000 similar: $25,000–$100,000 |
| EDGAR ↗ | Antiva Biosciences, Inc. | Director | Nov 3, 2021 | D | $31,001,635 similar: $2,000,000–$19,999,994 | $15,639,364 | 20 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Hyalex Orthopaedics, Inc. | Director | Jul 9, 2021 | D/A | $34,866,680 similar: $829,831–$9,999,998 | $30,604,063 | 22 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OncoResponse, Inc | Director | Mar 31, 2021 | D | $60,000,000 similar: $2,000,000–$19,999,994 | $40,625,995 | 14 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Glooko, Inc. | Director | Mar 17, 2021 | D | $35,000,000 similar: $829,831–$9,999,998 | $30,000,000 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Stargazer Pharmaceuticals, Inc. | Director | May 13, 2020 | D/A | $62,183,282 similar: $1,694,259–$16,000,000 | $28,461,471 | 9 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Qlaris Bio, Inc. | Director | Aug 28, 2019 | D | $27,325,180 similar: $2,000,000–$19,999,994 | $8,164,654 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Hyalex Orthopaedics, Inc. | Director | Mar 29, 2019 | D/A | $33,000,000 similar: $829,831–$9,999,998 | $15,531,398 | 22 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OncoResponse, Inc | Director | Sep 6, 2018 | D | $39,999,995 similar: $2,000,000–$19,999,994 | $18,999,999 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Antiva Biosciences, Inc. | Director | Jul 19, 2018 | D | $15,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Hyalex Orthopaedics, Inc. | Director | May 30, 2017 | D | $16,390,013 similar: $829,831–$9,999,998 | $9,305,398 | 19 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OncoResponse, Inc | Director | Mar 23, 2017 | D/A | $34,044,454 similar: $2,000,000–$19,999,994 | $29,499,000 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | REVISION OPTICS INC | Director | Nov 10, 2016 | D | $45,000,000 similar: $1,100,015–$10,001,163 | $31,973,690 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | CHRONO THERAPEUTICS INC. | Director | Sep 9, 2016 | D | $47,607,004 similar: $829,831–$9,999,998 | $37,606,945 | 22 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OncoResponse, Inc | Director | May 26, 2016 | D/A | $28,224,448 similar: $2,000,000–$19,999,994 | $19,499,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OncoResponse, Inc | Director | Oct 15, 2015 | D | $28,224,448 similar: $2,000,000–$19,999,994 | $16,499,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Antiva Biosciences, Inc. | Director | Jun 11, 2015 | D | $15,969,973 similar: $2,000,000–$19,999,994 | $8,907,483 | 26 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Butterfly Health, Inc. | Director | May 8, 2015 | D | $3,100,000 similar: $1,000,000–$7,247,539 | $3,056,409 | 45 similar: 2–13 | No minimum reported similar: $10,000–$60,000 |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | May 7, 2015 | D | $4,408,149 similar: $2,000,000–$19,999,994 | $3,080,000 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Transcend Medical Inc | Director | Jan 5, 2015 | D/A | $29,267,917 similar: $829,831–$9,999,998 | $29,267,917 | 18 similar: 2–15 | $1 similar: $10,000–$54,310 |
| EDGAR ↗ | Dermira, Inc. | Director | Sep 30, 2014 | D | $50,999,996 similar: $829,831–$9,999,998 | $50,999,991 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ALDEA Pharmaceuticals, Inc. | Director | Aug 25, 2014 | D | $24,058,143 similar: $2,000,000–$19,999,994 | $9,262,658 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CHRONO THERAPEUTICS INC. | Director | Jun 13, 2014 | D | $33,203,198 similar: $829,831–$9,999,998 | $13,282,116 | 31 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Transcend Medical Inc | Director | Apr 2, 2014 | D | $22,499,994 similar: $829,831–$9,999,998 | $21,999,994 | 15 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | ALDEA Pharmaceuticals, Inc. | Director | Nov 18, 2013 | D/A | $11,483,692 similar: $2,000,000–$19,999,994 | $11,380,718 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Butterfly Health, Inc. | Director | Sep 4, 2013 | D/A | $15,383,300 | $5,556,575 | 56 | No minimum reported |
| EDGAR ↗ | REVISION OPTICS INC | Director | Aug 2, 2013 | D | $39,699,993 | $39,699,993 | 13 | No minimum reported |
| EDGAR ↗ | Butterfly Health, Inc. | Director | Jul 30, 2013 | D | $15,383,300 | $2,785,899 | 3 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Jul 29, 2013 | D/A | $6,396,000 | $6,000,000 | 2 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Jul 29, 2013 | D | $6,396,000 | $6,000,000 | 2 | No minimum reported |
| EDGAR ↗ | Dermira, Inc. | Director | Jun 13, 2013 | D | $25,000,000 | $25,000,000 | 5 | No minimum reported |
| EDGAR ↗ | REVISION OPTICS INC | Director | Apr 16, 2013 | D | $14,999,998 | $14,999,998 | 8 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Mar 26, 2013 | D | $8,000,001 | $4,000,000 | 18 | No minimum reported |
| EDGAR ↗ | Labrys Biologics, Inc. group: Venbio | Director | Dec 28, 2012 | D | $30,999,997 | $14,588,234 | 5 | No minimum reported |
| EDGAR ↗ | Dermira, Inc. | Director | Sep 12, 2012 | D | $42,006,739 | $34,006,738 | 7 | No minimum reported |
| EDGAR ↗ | Butterfly Health, Inc. | Director | Sep 6, 2012 | D | $6,500,000 | $2,219,457 | 11 | No minimum reported |
| EDGAR ↗ | ALDEA Pharmaceuticals, Inc. | Director | May 8, 2012 | D/A | $7,382,620 | $4,513,491 | 6 | No minimum reported |
| EDGAR ↗ | Altheos, Inc. | Director | Feb 23, 2012 | D/A | $16,560,013 | $16,560,013 | 6 | No minimum reported |
| EDGAR ↗ | ALDEA Pharmaceuticals, Inc. | Director | Feb 15, 2012 | D/A | $1,277,000 | $1,277,000 | 5 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Nov 23, 2011 | D/A | $11,584,603 | $11,584,603 | 13 | No minimum reported |
| EDGAR ↗ | ALDEA Pharmaceuticals, Inc. | Director | Oct 6, 2011 | D | $1,027,000 | $1,027,000 | 4 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Sep 12, 2011 | D | $10,584,603 | $10,584,603 | 12 | No minimum reported |
| EDGAR ↗ | Altheos, Inc. | Director | Jul 25, 2011 | D | $6,560,014 | $6,560,014 | 6 | No minimum reported |
| EDGAR ↗ | Transcend Medical Inc | Director | Jul 14, 2011 | D | $27,571,428 | $27,571,426 | 15 | No minimum reported |
| EDGAR ↗ | Calibra Medical, Inc. | Director | Apr 14, 2011 | D | $30,000,000 | $8,110,136 | 6 | No minimum reported |
| EDGAR ↗ | Calibra Medical, Inc. | Director | Mar 4, 2011 | D | $1,000,000 | $1,000,000 | 5 | No minimum reported |
| EDGAR ↗ | REVISION OPTICS INC | Director | May 18, 2010 | D | $35,000,000 | $35,000,000 | 11 | No minimum reported |
| EDGAR ↗ | Theraclone Sciences, Inc. | Director | Mar 17, 2010 | D | $1,500,000 | $1,500,000 | 1 | No minimum reported |
| EDGAR ↗ | Calibra Medical, Inc. | Director | Feb 22, 2010 | D | $32,286,257 | $9,317,895 | 6 | No minimum reported |
| EDGAR ↗ | Calibra Medical, Inc. | Director | Nov 20, 2009 | D | $1,400,000 | $1,400,000 | 6 | No minimum reported |
| EDGAR ↗ | Transcend Medical Inc | Director | Aug 20, 2009 | D/A | $41,000,001 | $23,428,572 | 12 | No minimum reported |
| EDGAR ↗ | Transcend Medical Inc | Director | May 28, 2009 | D | $40,000,000 | $19,999,999 | 8 | No minimum reported |
| EDGAR ↗ | Apieron Inc | Director | Apr 7, 2009 | D | $16,000,000 | $5,924,643 | 9 | No minimum reported |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Wende Hutton. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Wende Hutton appears on a new Form D, or when a court case or SEC action is matched to them. See plans →